Tumor-infiltrating lymphocyte (TIL) cells
Executive Summary
Pending IND for a gene marker-inserted TIL cell product will be discussed by FDA's Vaccines and Related Biological Products Advisory Committee at its Dec. 19 meeting. The panel will meet at Lister Hill Auditorium on the NIH campus beginning at 8:30 a.m....